
Real-World Treatment Gaps in mCRPC Reinforce the Need for Personalized Selection and Sequencing
Despite the growing availability of effective agents in the metastatic castration-resistant prostate cancer (mCRPC) treatment arsenal, suboptimal treatment patterns and ensuing gaps between therapeutic advancements and real-world patient outcomes persist, …